Plain-English translation of NCT07157345 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a first-in-human trial testing PDR-001, a new injectable treatment designed to target and clear a harmful protein called alpha-synuclein that accumulates in Parkinson's disease. Instead of just managing symptoms like current treatments do, this medication aims to address the root cause of the disease. Researchers will carefully monitor your safety and whether the treatment works.
Current Parkinson's treatments help with symptoms but don't stop the disease from getting worse. This trial exists because lab and animal studies show that the medication can effectively clear the harmful protein buildup that drives Parkinson's progression, offering hope for a treatment that could actually slow or halt the disease.
You likely qualify if…
You likely don't qualify if…
You would undergo a surgical procedure in which researchers inject the medication directly into a specific area of your brain (the subthalamic nucleus) on both sides using a precise stereotactic technique. This is a one-time treatment. You would then be carefully monitored with follow-up visits and tests to ensure your safety and to measure whether the medication is helping reduce your symptoms and slow disease progression.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China